dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: CD molecules (type: other_protein)
Target: CD47

Ligand: thrombospondin 1 (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin.
Published in: J Biol Chem

Ligand: ontorpacept (Peptide)
Interaction type: Fusion protein
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.849999904632568 pEC50
Reference (Journal): TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Published in: Clin Cancer Res

Ligand: magrolimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pKd
Reference (Journal): Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Published in: PLoS ONE

Ligand: magrolimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 11.100000381469727 pKd
Reference (Journal): Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Published in: PLoS ONE

Ligand: evorpacept (Peptide)
Interaction type: Fusion protein
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9 pKd
Reference (Journal): ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Published in: PLoS One

Ligand: evorpacept (Peptide)
Interaction type: Fusion protein
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.020000457763672 pKd
Reference (Journal): ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Published in: PLoS One

Ligand: evorpacept (Peptide)
Interaction type: Fusion protein
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.590000152587891 pKd
Reference (Journal): ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Published in: PLoS One

Ligand: evorpacept (Peptide)
Interaction type: Fusion protein
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.239999771118164 pKd
Reference (Journal): ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Published in: PLoS One
Target family: CD molecules (type: other_protein)
Target: CD4

Ligand: tregalizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): Humanized anti-cd4 antibody with immunosuppressive properties.

Ligand: ibalizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2018), EMA (2019)
Primary target: yes
Median affinity:  -
Reference (Journal): Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion.
Published in: J Immunol
Target family: CD molecules (type: other_protein)
Target: CD38

Ligand: MK-0159 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.659999847412109 pIC50
Reference (Journal): Orally Bioavailable Enzymatic Inhibitor of CD38, <b>MK-0159</b>, Protects against Ischemia/Reperfusion Injury in the Murine Heart.
Published in: J Med Chem

Ligand: MK-0159 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pIC50
Reference (Journal): Orally Bioavailable Enzymatic Inhibitor of CD38, <b>MK-0159</b>, Protects against Ischemia/Reperfusion Injury in the Murine Heart.
Published in: J Med Chem

Ligand: mezagitamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.260000228881836 pKd
Reference (Patent): Anti-cd38 antibodies

Ligand: isatuximab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: EMA & FDA (2020)
Primary target: yes
Median affinity:  pKd
Reference (Patent): Novel anti-cd38 antibodies for the treatment of cancer.

Ligand: daratumumab (Antibody)
Interaction type: Antibody
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2015), EMA (2017)
Primary target: yes
Median affinity: 8.220000267028809 pKd
Reference (Patent): Antibodies Against Cd38 For Treatment Of Multiple Myeloma.
Target family: CD molecules (type: other_protein)
Target: CD37 molecule

Ligand: otlertuzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
Published in: MAbs

Ligand: naratuximab emtansine (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.300000190734863 pEC50
Reference (Journal): A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
Published in: Blood

Ligand: lilotomab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 8.569999694824219 pKd
Reference (Journal): Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
Published in: Anticancer Res
Target family: CD molecules (type: other_protein)
Target: CD36 molecule (CD36 blood group)

Ligand: thrombospondin 1 (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: peptide 5A (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation.
Published in: Kidney Int

Ligand: peptide 1 [PMID: 31774287] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.099999904632568 pKd
Reference (Journal): Dynamic Chirality in the Mechanism of Action of Allosteric CD36 Modulators of Macrophage-Driven Inflammation.
Published in: J Med Chem

Ligand: compound 3c [PMID: 30360354] (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.599999904632568 pIC50
Reference (Journal): Azapeptide analogues of the growth hormone releasing peptide 6 as cluster of differentiation 36 receptor ligands with reduced affinity for the growth hormone secretagogue receptor 1a.
Published in: J Med Chem
Target family: CD molecules (type: other_protein)
Target: CD33

Ligand: vadastuximab talirine (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.300000190734863 pKd
Reference (Journal): SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
Published in: Blood

Ligand: lintuzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 10 pKd
Reference (Journal): Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
Published in: Cancer Res

Ligand: gemtuzumab ozogamicin (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2000), EMA (2018)
Primary target: yes
Median affinity:  -
Reference (Journal): Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.
Published in: Leukemia
Target family: CD molecules (type: other_protein)
Target: CD28

Ligand: lulizumab pegol (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  pKd
Reference (Journal): A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety.
Published in: J Immunol
Target family: CD molecules (type: other_protein)
Target: CD22

Ligand: moxetumomab pasudotox (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2018), EMA (2021)
Primary target: yes
Median affinity: 8.220000267028809 pKd
Reference (Patent): Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells.

Ligand: moxetumomab pasudotox (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2018), EMA (2021)
Primary target: yes
Median affinity: 8.220000267028809 pKd
Reference (Journal): Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
Published in: J Clin Oncol

Ligand: moxetumomab pasudotox (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2018), EMA (2021)
Primary target: yes
Median affinity: 8.220000267028809 pKd
Reference (Journal): Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Published in: Clin Cancer Res

Ligand: inotuzumab ozogamicin (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: EMA & FDA (2017)
Primary target: yes
Median affinity: 9.699999809265137 pKd
Reference (Journal): Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
Published in: Blood
Target family: CD molecules (type: other_protein)
Target: CD2

Ligand: alefacept (Peptide)
Interaction type: Fusion protein
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2003)
Primary target: yes
Median affinity:  -
Reference (Journal): Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.
Published in: J Immunol

Ligand: alefacept (Peptide)
Interaction type: Fusion protein
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2003)
Primary target: yes
Median affinity:  -
Reference (Journal): First biotech drug to treat psoriasis.
Published in: Nat Biotechnol
Target family: CD molecules (type: other_protein)
Target: CD1d molecule

Ligand: AH10-7 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity.
Published in: Cell Chem Biol
Target family: CD molecules (type: other_protein)
Target: CD19

Ligand: tafasitamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2020), EMA (2021)
Primary target: yes
Median affinity:  -
Reference (Journal): Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Published in: Cancer Res

Ligand: loncastuximab tesirine (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2021), EMA (2022)
Primary target: no
Median affinity:  -
Reference (Journal): ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
Published in: Blood

Ligand: inebilizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2020), EMA (2022)
Primary target: yes
Median affinity:  pKd
Reference (Patent): Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease.

Ligand: blinatumomab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2014), EMA (2015)
Primary target: no
Median affinity: 9 pKd
Reference (Journal): Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.
Published in: Int J Cancer
Target family: CD molecules (type: other_protein)
Target: CD14 molecule

Ligand: atibuclimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis.
Published in: J Endotoxin Res

Ligand: atibuclimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14).
Published in: Crit Care Med
Target family: CD molecules (type: other_protein)
Target: basigin (Ok blood group)

Ligand: meplazumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: CD molecules (type: other_protein)
Target: B7-H3 (CD276)

Ligand: obrindatamab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): Antibodies reactive with B7-H3 and uses thereof

Ligand: enoblituzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 7.610000133514404 pKd
Reference (Journal): Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Published in: Clin Cancer Res

Ligand: enoblituzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.650000095367432 pKd
Reference (Journal): Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Published in: Clin Cancer Res
Target family: CD molecules (type: other_protein)
Target: transferrin receptor (CD71)

Ligand: pabinafusp alfa (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: Japan (2021)
Primary target: no
Median affinity:  -
Reference (Journal): A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
Published in: Mol Ther

Ligand: pabinafusp alfa (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: Japan (2021)
Primary target: no
Median affinity:  -
Reference (Patent): Novel anti-transferrin receptor antibody that passes through blood-brain barrier

Ligand: lepunafusp alfa (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): Novel anti-transferrin receptor antibody that passes through blood-brain barrier
Target family: CD molecules (type: other_protein)
Target: TIM3 (CD366)

Ligand: sabatolimab (Antibody)
Interaction type: Antibody
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.319999694824219 pIC50
Reference (Journal): Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Published in: Immunother Adv

Ligand: sabatolimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.779999732971191 pKd
Reference (Journal): Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Published in: Immunother Adv

Ligand: sabatolimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.140000343322754 pKd
Reference (Journal): Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Published in: Immunother Adv
Target family: CD molecules (type: other_protein)
Target: SIRPA (CD172a)

Ligand: thrombospondin 1 (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Target family: CD molecules (type: other_protein)
Target: semaphorin 4D (CD100)

Ligand: pepinemab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.350000381469727 pKd
Reference (Journal): Generation and preclinical characterization of an antibody specific for SEMA4D.
Published in: MAbs
Target family: CD molecules (type: other_protein)
Target: selectin P (CD62)

Ligand: selectin P ligand (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 6.489999771118164 pKd
Reference (Journal): Affinity and kinetic analysis of P-selectin binding to P-selectin glycoprotein ligand-1.
Published in: J Biol Chem

Ligand: rivipansel (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 3.369999885559082 pIC50
Reference (Journal): GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.
Published in: Blood

Ligand: inclacumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): Anti-p-selectin antibodies

Ligand: crizanlizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2019), EMA (2020)
Primary target: no
Median affinity: 8.229999542236328 pKd
Reference (Patent): Anti-p-selectin antibodies and methods of their use and identification

Ligand: bimosiamose (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 4.150000095367432 pIC50
Reference (Journal): Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4-(2-alpha-D- mannopyranosyloxy)phenyl]hexane (TBC1269).
Published in: J Med Chem
Target family: CD molecules (type: other_protein)
Target: selectin E (CD62E)

Ligand: uproleselan (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.760000228881836 pIC50
Reference (Journal): Targeting E-selectin to Tackle Cancer Using Uproleselan.
Published in: Cancers (Basel)

Ligand: uproleselan (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.340000152587891 pKd
Reference (Journal): Targeting E-selectin to Tackle Cancer Using Uproleselan.
Published in: Cancers (Basel)
Target family: Ceramide glucosyltransferase (type: enzyme)
Target: UDP-glucose ceramide glucosyltransferase

Ligand: miglustat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (2002), FDA (2003)
Primary target: yes
Median affinity: 5.130000114440918 pKi
Reference (Journal): Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis.
Published in: Tetrahedron: Assymetry

Ligand: T-690 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.820000171661377 pIC50
Reference (Journal): Discovery of Brain-Penetrant Glucosylceramide Synthase Inhibitors with a Novel Pharmacophore.
Published in: J Med Chem

Ligand: venglustat (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.300000190734863 pIC50
Reference (Patent): Glucosylceramide synthase inhibitors
Target family: Ceramide kinase (type: enzyme)
Target: ceramide kinase

Ligand: NVP 231 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.9 pIC50
Reference (Journal): Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor.
Published in: Mol Pharmacol
Target family: ChaK subfamily (type: enzyme)
Target: TRPM6

Ligand: 2-APB (Synthetic organic)
Interaction type: Activator
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7.
Published in: J Gen Physiol

Ligand: Ca2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  pIC50

Ligand: H+ (Inorganic)
Interaction type: Activator
Action: Potentiation
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: Mg2+ (Inorganic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: Mg2+ (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Median affinity:  pIC50

Ligand: Mg2+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity: 3.3 pIC50
Reference (Journal): TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption.
Published in: J Biol Chem

Ligand: ruthenium red (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: no
Median affinity:  -
Reference (Journal): TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption.
Published in: J Biol Chem

Ligand: ruthenium red (Inorganic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Target family: Chemerin receptors (type: gpcr)
Target: chemerin receptor 2

Ligand: OSTN (81-102) (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.179999828338623 pEC50
Reference (Journal): Discovery of Human Signaling Systems: Pairing Peptides to G Protein-Coupled Receptors.
Published in: Cell

Ligand: chemerin C-terminal peptide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9 pEC50
Reference (Journal): The genetic design of signaling cascades to record receptor activation.
Published in: Proc Natl Acad Sci USA

Ligand: chemerin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Screening β-Arrestin Recruitment for the Identification of Natural Ligands for Orphan G-Protein-Coupled Receptors.
Published in: J Biomol Screen

Ligand: chemerin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.28 pKd
Reference (Journal): The genetic design of signaling cascades to record receptor activation.
Published in: Proc Natl Acad Sci USA

Ligand: chemerin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): The genetic design of signaling cascades to record receptor activation.
Published in: Proc Natl Acad Sci USA
Target family: Chemokine receptors (type: gpcr)
Target: CCR4

Ligand: CCL22 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.2 pIC50
Reference (Journal): Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4.
Published in: J Biol Chem